---
title: "Pfizer GLP-1 weight loss drug available for pre-order in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283631330.md"
datetime: "2026-04-22T09:14:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283631330.md)
  - [en](https://longbridge.com/en/news/283631330.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283631330.md)
---

# Pfizer GLP-1 weight loss drug available for pre-order in China

By Andrew Silver

SHANGHAI, April 22 (Reuters) - Pfizer’s GLP-1 weight management treatment Xianweiying is available for pre-order in China, a Reuters check on a local e-commerce platform showed, ramping up competition with rivals in a market analysts expect to be worth billions of dollars.

A spokesperson for Pfizer did not immediately respond to a request for comment.

A 1.2 ml Xianweiying injector pen with shipping beginning on April 27 costs 489 yuan ($72), according to one listing on a platform from JD.com reviewed by Reuters.

The treatment, belonging to the class of GLP-1 receptor agonist drugs sold locally by drugmakers such as Novo Nordisk (NOVOb.CO) , Eli Lilly (LLY.N) , and Innovent Biologics (1801.HK) , props up Pfizer’s footing in the booming weight-loss drug market.

Sales of Novo’s Wegovy on Alibaba’s (9988.HK) Tmall e-commerce platform and JD.com (9618.HK) were 260 million yuan ($38 million) in 2025, against 416 million yuan ($61 million) for Innovent’s Xinermei, investment bank Jefferies said in a note.

Pfizer (PFE.N) licensed the mainland China commercialisation rights for Xianweiying, also known as ecnoglutide, from Sciwind, based in the eastern city of Hangzhou, in February. It has also recently acquired the obesity drug developer Metsera, as well as another experimental GLP-1 drug from another developer.

Ecnoglutide is also approved in China as a treatment for Type 2 diabetes.

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [09618.HK](https://longbridge.com/en/quote/09618.HK.md)
- [JD.US](https://longbridge.com/en/quote/JD.US.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [09988.HK](https://longbridge.com/en/quote/09988.HK.md)
- [BABA.US](https://longbridge.com/en/quote/BABA.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [MTSR.US](https://longbridge.com/en/quote/MTSR.US.md)
- [89618.HK](https://longbridge.com/en/quote/89618.HK.md)
- [89988.HK](https://longbridge.com/en/quote/89988.HK.md)
- [HBBD.SG](https://longbridge.com/en/quote/HBBD.SG.md)

## Related News & Research

- [GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy?](https://longbridge.com/en/news/284837521.md)
- [More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo, CEO says](https://longbridge.com/en/news/284772786.md)
- [Pfizer deals extend patent life for a top-selling rare disease drug](https://longbridge.com/en/news/284784349.md)
- [12:27 ETFuturHealth Among the First to Offer Eli Lilly's Oral GLP-1, Orforglipron, Expanding Access to Next-Generation, Non-Injectable Treatment](https://longbridge.com/en/news/284423387.md)
- [Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch](https://longbridge.com/en/news/284912732.md)